A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y<sub>12</sub> Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention The INNOVATE-PCI Trial

INNOVATE-PEI Investigators, Martin Edelman

Research output: Contribution to journalArticlepeer-review

87 Scopus citations
Original languageEnglish
Pages (from-to)336-346
Number of pages11
JournalCirculation: Cardiovascular Interventions
Volume5
Issue number3
DOIs
StatePublished - Jun 2012

Keywords

  • Antiplatelets
  • Cardiovascular pharmacology
  • Catheter based coronary interventions
  • Chronic ischemic heart disease
  • Platelet function inhibitors

Fingerprint

Dive into the research topics of 'A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y<sub>12</sub> Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention The INNOVATE-PCI Trial'. Together they form a unique fingerprint.

Cite this